Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 September 2022 | Story Andrè Damons | Photo Andrè Damons
Prof Abdon Atangana
Prof Abdon Atangana, Professor of Applied Mathematics in the Institute for Groundwater Studies (IGS) and a highly cited mathematician for the years 2019-2021, says existing mathematical models are used to first fit collected data and then predict future events. It is for this reason he introduced a new concept that can be used to test whether the spread will have one or several waves.

With a new outbreak of the Ebola Virus Disease (EVD) reported this year in Democratic Republic of the Congo (DRC) – the 14th EVD outbreak in the country – researchers at the University of the Free State (UFS) introduced a new concept that can be used to test whether the spread will have one or several waves. They believe the focus should be to identify the source or the hosts of this virus for it to be a complete eradication. 

According to the Centers for Disease Control and Prevention (CDC), the Ministry of Health in the Democratic Republic of the Congo (DRC) declared an outbreak of Ebola in Mbandaka health zone, Equateur Province on April 23, 2022. EVD, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness affecting humans and other primates. The virus is transmitted to people from wild animals (such as fruit bats, porcupines and non-human primates) and then spreads in the human population through direct contact with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids, according to the World Health Organisation (WHO).
 
Prof Abdon Atangana, Professor of Applied Mathematics in the Institute for Groundwater Studies (IGS), says existing mathematical models are used to first fit collected data and then predict future events. Predictions help lawmakers to take decisions that will help protect their citizens and their environments. The outbreaks of COVID-19 and other infectious diseases have exposed the weakness of these models as they failed to predict the number of waves and in several instances; they failed to predict accurately day-to-day new infections, daily deaths and recoveries.

Solving the challenges of the current models

In the case of COVID-19 in South Africa, it is predicted that the country had far more infections than what was recorded, which is due to challenges faced by the medical facilities, poverty, inequality, and other factors. With Ebola in the DRC, data recorded are not far from reality due to the nature of the virus and its symptoms. However, the predictions show although some measures have been put in place in DRC and other places where the Ebola virus spread, they will still face some challenges in the future, as the virus will continue to spread but may have less impact. 

“To solve the challenges with the current models, we suggested a new methodology. We suggested that each class should be divided into two subclasses (Detected and undetected) and we also suggested that rates of infection, recovery, death and vaccination classes should be a function of time not constant as suggested previously. These rates are obtained from what we called daily indicator functions. For example, an infection rate should be obtained from recorded data with the addition of an uncertain function that represents non-recorded data (Here more work is still to be done to get a better approximation).

“I introduced a new concept called strength number that can be used to test whether the spread will have one or several waves. The strength number is an accelerative force that helps to provide speed changes, thus if this number is less than zero we have deceleration, meaning there will be a decline in the number of infections. If the number is positive, we have acceleration, meaning we will have an increase in numbers. If the number is zero, the current situation will remain the same,” according to Prof Atangana. 

To provide better prediction, he continues, reliable data are first fitted with the suggested mathematical model. This helps them to know if their mathematical model is replicating the dynamic process of the spread. The next step is to predict future events, to do this, we create three sub-daily indicator functions (minimum, actual, and maximum). These will lead to three systems, the first system represents the worst-case scenario, the second is the actual scenario, and the last is a best-case scenario.

Virus will continue to spread but with less impact

Using this method, Prof Atangana, a highly cited mathematician for the years 2019-2021, says he and Dr Seda Igret Araz, postdoctoral student, were able to predict that, although some measures have been put in place in DRC and other places where the Ebola virus spreads, they will still face some challenges in the future as the virus will continue to spread but may have less impact. 

To properly achieve the conversion from observed facts into mathematical formulations and to address these limitations, he had to ask fundamental questions such as what is the rate of infection, what is the strength of the infection, what are the crossover patterns presented by the spread, how can day-to-day new infected numbers be predicted and what differential operator should be used to model a dynamic process followed by the spread?

This approach was tested for several infectious diseases where we present the case of Ebola in Congo and Covid-19 in South Africa.  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept